SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-010302
Filing Date
2023-05-22
Accepted
2023-05-22 16:01:39
Documents
63
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q nbrv-20230331x10q.htm   iXBRL 10-Q 1126626
2 EX-31.1 nbrv-20230331xex31d1.htm EX-31.1 11258
3 EX-31.2 nbrv-20230331xex31d2.htm EX-31.2 11268
4 EX-32.1 nbrv-20230331xex32d1.htm EX-32.1 6704
5 EX-32.2 nbrv-20230331xex32d2.htm EX-32.2 6283
  Complete submission text file 0001558370-23-010302.txt   5630639

Data Files

Seq Description Document Type Size
6 EX-101.SCH nbrv-20230331.xsd EX-101.SCH 55853
7 EX-101.CAL nbrv-20230331_cal.xml EX-101.CAL 50092
8 EX-101.DEF nbrv-20230331_def.xml EX-101.DEF 214410
9 EX-101.LAB nbrv-20230331_lab.xml EX-101.LAB 462826
10 EX-101.PRE nbrv-20230331_pre.xml EX-101.PRE 331824
57 EXTRACTED XBRL INSTANCE DOCUMENT nbrv-20230331x10q_htm.xml XML 798290
Mailing Address 414 COMMERCE DRIVE STE 120 FORT WASHINGTON PA 19034
Business Address 25-28 NORTH WALL QUAY DUBLIN L2 D01 H104 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37558 | Film No.: 23944343
SIC: 2834 Pharmaceutical Preparations